Mosaic ImmunoEngineering CPMV

Mosaic ImmunoEngineering, Inc. is a development stage biotechnology company that was formed through the combination of Private Mosaic and Patriot Scientific Corporation via a reverse merger completed on August 21, 2020. The company’s primary focus is the research and development of immunotherapies designed to treat cancer by stimulating the immune system to recognize and destroy tumor cells. Mosaic ImmunoEngineering, Inc. holds an exclusive license from Case Western Reserve University for the cowpea mosaic virus platform, which it intends to use as a foundation for developing novel therapeutic candidates. The cowpea mosaic virus platform is being investigated for its ability to stimulate innate and adaptive immune responses, potentially providing a versatile tool for oncology indications. The company operates in the biotechnology and pharmaceutical sector, with all efforts directed toward advancing early stage product candidates through preclinical studies and seeking partnerships or acquisitions to expand its pipeline.

Mosaic ImmunoEngineering, Inc. currently generates limited revenue from providing advisory and related services to collaborators, such as the fees earned under its Master Services Agreement with Oncotelic Therapeutics, Inc., which amounted to fourteen thousand dollars in 2025 and forty two thousand dollars in 2024. The company also records interest income on convertible notes issued to investors, although such interest is classified as other income rather than operating revenue. Interest accrued on convertible notes is tracked separately and contributes to the company’s overall non operating income. Mosaic ImmunoEngineering, Inc. has not yet commercialized any therapeutic product and therefore does not receive product sales, licensing royalties or milestone payments at this time. Future revenue will depend on the successful advancement of its immunotherapy candidates into clinical trials and eventual regulatory approval.

The company operates through the following segment.

• Single Operating Segment: the company’s sole operating segment concentrates on the research and development of immunotherapy candidates for cancer treatment, encompassing preclinical laboratory studies, animal model testing, preparation of investigational new drug applications, and efforts to license or acquire additional product candidates or platform technologies from third parties. The segment also includes activities related to regulatory strategy, manufacturing planning and the identification of biomarker correlates for clinical endpoints.

Mosaic ImmunoEngineering, Inc. occupies an early stage position in the highly competitive immuno oncology landscape, where it faces substantial competition from large pharmaceutical and biotechnology firms such as Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, Roche and Sanofi. These established competitors possess extensive financial resources, global manufacturing capabilities, established sales and marketing infrastructures, and deep pipelines of approved immuno oncology therapies. Despite its limited scale, Mosaic ImmunoEngineering, Inc. seeks to differentiate itself through its specialized scientific expertise in immunotherapy, its access to novel academic derived platform technologies such as the cowpea mosaic virus system, and its flexibility to pursue innovative targets through strategic partnerships or acquisitions. The company’s strategy emphasizes identifying high potential candidates that address unmet medical needs and leveraging external expertise to advance development efficiently. Additionally, the company’s lean organizational structure allows it to make rapid decisions and allocate capital efficiently toward promising projects.

Mosaic ImmunoEngineering, Inc. currently provides advisory services to Oncotelic Therapeutics, Inc., which constitutes its primary known customer and generated the fee income reported in other income. The company also maintains relationships with academic institutions such as Case Western Reserve University through licensing agreements, although these arrangements do not constitute customer revenue. Looking ahead, Mosaic ImmunoEngineering, Inc. anticipates serving hospitals, clinics and patients once its immunotherapy candidates receive regulatory approval and achieve commercialization. Until such time, the company’s interactions are primarily with potential collaborators, licensors and investors who support its research and development efforts. In the interim, the company engages with contract research organizations and consultants to support preclinical and clinical development activities.